Efficacy and Safety of High-Concentration 35 kDa Hyaluronan Gel for Chronic Nasopharyngitis (HA35)
A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate Efficacy and Safety of Topical 10% 35 kDa Hyaluronan (HA35) Gel for Ultra-Rapid Relief of Skin Pruritus
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This prospective, single-center, single-arm, open-label pilot clinical study is designed to investigate the efficacy and safety of a 13.6% high-concentration 35 kDa hyaluronan (HA35) nasopharyngeal care gel for the management of chronic rhinitis and chronic pharyngitis.
Participants meeting all eligibility criteria will receive the HA35 gel via nasopharyngeal administration, one unit per nostril, twice daily (morning and evening) for 10 consecutive days.
Symptom assessments will be performed at baseline, 30 minutes after the first administration, 1, 2, and 3 hours after the first morning dose, and on day 10. Assessments include numeric rating scales (NRS) for nasopharyngeal discomfort, posterior pharyngeal discomfort and cough, nasal airflow obstruction, overall rhinitis and pharyngitis symptom severity, and subjective mental clarity.
Safety evaluations will monitor all adverse events, local tolerability, and any unexpected reactions throughout the study period.
This study involves a non-invasive, non-pharmacological non-drug intervention with minimal risk to participants. All procedures will be conducted in accordance with the Declaration of Helsinki, and written informed consent will be obtained from all subjects prior to enrollment.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Age 18-80 years, male or female
- Clinically diagnosed with chronic rhinitis and chronic pharyngitis for ≥3 months
- Baseline nasopharyngeal discomfort NRS score ≥4 points
- Baseline posterior pharyngeal discomfort NRS score ≥4 points
- Voluntary participation and signed written informed consent
- Ability to complete symptom assessment independently
Exclusion Criteria:
- Acute upper respiratory tract infection within 2 weeks
- Use of antihistamines, intranasal corticosteroids, decongestants, or other nasal medications within 2 weeks prior to screening
- History of nasal/sinus surgery within 6 months
- Known hypersensitivity to hyaluronan or any gel ingredients
- Pregnant or lactating women
- Severe systemic diseases or malignant tumors
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Stödjande vård
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: HA35 Nasopharyngeal Care Gel Intervention Group
Participants will receive 13.6% high-concentration 35 kDa hyaluronan (HA35) nasopharyngeal care gel, administered via the nasopharyngeal route, one unit per nostril, twice daily (morning and evening) for 10 consecutive days.
The intervention is non-pharmacological and designed to evaluate efficacy and safety in subjects with chronic rhinitis and chronic pharyngitis.
|
A topical, non-pharmacological nasopharyngeal care gel containing 13.6% high-concentration 35 kDa hyaluronan.
It is designed to support mucosal hydration and reduce inflammation in the nasopharynx.
Administration is via direct nasopharyngeal application, twice daily for 10 consecutive days.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Posterior Pharyngeal Discomfort and Cough NRS Score (0-10)
Tidsram: Baseline to 30 minutes after first administration
|
Change in posterior pharyngeal discomfort and associated cough intensity, measured using a 0-10 Numeric Rating Scale (NRS), where 0 = no discomfort/cough and 10 = worst imaginable discomfort/cough.
|
Baseline to 30 minutes after first administration
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- HA35202601
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .